title: Prognostic significance of Bcl-2 and p53 expression in advanced laryngeal squamous cell carcinoma.
abstract: BACKGROUND
  Proteins regulating the cell cycle and cell death are frequently abnormally expressed in cancer. Several of these, particularly p53 and Bcl-2, have been widely suggested as possible prognostic markers in diverse human malignancies. Their role in predicting outcome in squamous cell carcinomas of the head and neck is unclear and may depend on the location, stage, and treatment of the tumor.
  
  
  METHODS
  To assess this question specifically for advanced squamous cell carcinoma of the larynx, we studied 69 patients with stage III or IV tumors, all but 6 of whom were treated with surgery plus postoperative irradiation by a single physician. We studied the patients retrospectively to test the association between expression of Bcl-2 and p53, as assessed by immunohistochemistry, with treatment outcome and survival.
  
  
  RESULTS
  Twenty of the 69 patients died from their tumor (poor outcome); the rest were alive and tumor free at the last follow-up or died of unrelated causes without clinical tumor recurrence (good outcome). Fourteen tumors had detectable Bcl-2 expression, including 8 scored as overexpressors. Thirty-nine tumors overexpressed p53. Expression of neither Bcl-2 nor p53 was associated with outcome, overall survival, or disease-free survival. Only tumor stage was significantly associated with outcome and disease-free survival.
  
  
  CONCLUSIONS
  These data indicate that assessing expression of p53 or Bcl-2 is unlikely to be prognostically useful for surgically treated advanced laryngeal carcinoma.
authors.affiliation: Department of Otolaryngology, Rush Medical College of Rush University, Rush-Presbyterian-St. Luke's Medical Center, 30 North Michigan Avenue, Suite 1107, Chicago, Illinois 60602, USA.
authors.forename: M
authors.initials: M
authors.lastname: Friedman
authors.forename: J W
authors.initials: JW
authors.lastname: Lim
authors.forename: E
authors.initials: E
authors.lastname: Manders
authors.forename: A D
authors.initials: AD
authors.lastname: Schaffner
authors.forename: G L
authors.initials: GL
authors.lastname: Kirshenbaum
authors.forename: H M
authors.initials: HM
authors.lastname: Tanyeri
authors.forename: D D
authors.initials: DD
authors.lastname: Caldarelli
authors.forename: J S
authors.initials: JS
authors.lastname: Coon
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007822:Laryngeal Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism*; D016019:Survival Analysis; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
chemical_list: D019253:Proto-Oncogene Proteins c-bcl-2; D016159:Tumor Suppressor Protein p53